Business Context and Reporting Period
This Form 8-K Current Report, dated November 3, 2020, details material definitive agreements entered into by Aquestive Therapeutics, Inc. (AQST). The filing focuses on a restructuring of the Company's senior secured notes, the monetization of its Apomorphine royalty rights, and the issuance of unregistered equity warrants.
Key Financial Metrics and Transaction Details
- Debt Restructuring: The Company agreed to issue an additional $4.0 million in 12.5% senior secured notes due 2025 (Additional Notes) to existing holders for no additional cash consideration.
- Debt Repurchase: The Company committed to repurchase $22.5 million of existing notes at 100% of principal plus accrued interest.
- Asset Monetization: The Company sold all rights to royalties and milestone payments from its Apomorphine license with Sunovion Pharmaceuticals Inc. for an upfront payment of $40.0 million and potential contingent payments of up to $85.0 million.
- Equity Issuance: The Company issued warrants to purchase 143,000 shares of common stock immediately, with contingent warrants for an additional 714,000 shares tied to future note issuances.
- Cash Payments: A consent payment of $2.25 million in cash was made to certain purchasers.
- Debt Capacity: The maximum aggregate principal amount of notes issuable under the indenture was increased to $104.0 million.
Material Changes Versus Prior Period
The filing represents a significant change in the Company's capital structure and asset base compared to the prior period:
- Indenture Modification: The Base Indenture (July 2019) was amended to replace the "Apomorphine Asset Sale Offer" provisions with a new obligation to offer repurchases at 112.5% of principal using 30% of future Apomorphine monetization proceeds.
- Collateral Account: The Company is now permitted to retain net proceeds from the upfront Apomorphine payment outside of the Collateral Account, providing greater liquidity flexibility.
- Extension of Issuance Rights: The deadline for issuing additional notes based on FDA approval of the drug candidate Libervant was extended from March 31, 2021, to December 31, 2021.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The transactions are designed to reduce debt obligations while securing immediate liquidity through the sale of royalty rights. The Company retains the option to issue up to an additional $40.0 million in notes contingent upon FDA approval of Libervant by December 31, 2021.
Risks and Contingencies:
- Closing Conditions: The issuance of Additional Notes and the repurchase of existing notes are subject to closing conditions, including the receipt of upfront proceeds from the Apomorphine Monetization.
- Regulatory Approval: Future debt issuance options are contingent on FDA approval of Libervant, which carries inherent regulatory risk.
- Dilution: The issuance of warrants (up to 857,000 shares total) introduces potential dilution to existing shareholders.
Investor Verification Checklist
- Verify the closing of the $40.0 million upfront payment from MAM Pangolin Royalty, LLC.
- Confirm the successful repurchase of $22.5 million in notes and the issuance of the $4.0 million Additional Notes.
- Monitor the status of FDA approval for Libervant to determine if the Company will exercise its option to issue the First or Second Additional Notes by December 31, 2021.
- Review the terms of the 112.5% repurchase offer to understand future obligations if additional Apomorphine monetization proceeds are received.